Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NERV
- Price
- 1.57
- Stock movement up
- +0.12 (8.12%)
- Company name
- Minerva Neurosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 10.96M
- Ent value
- 48.92M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -14.92%
- 1 year return
- -38.28%
- 3 year return
- -38.24%
- 5 year return
- -49.07%
- 10 year return
- -27.98%
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NERV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | 3.96 |
| EV to EBITDA | 17.68 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.99M |
| EPS (TTM) | -0.44 |
| FCF per share (TTM) | -214748.36 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -28.86K |
| Operating income (TTM) | -24.50M |
| Net income (TTM) | -3.31M |
| EPS (TTM) | -0.44 |
| EPS (1y forward) | -2.68 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.53M |
| Net receivables | 0.00 |
| Total current assets | 27.94M |
| Goodwill | 14.87M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 42.81M |
| Accounts payable | 553.19K |
| Short/Current long term debt | 60.00M |
| Total current liabilities | 4.48M |
| Total liabilities | 64.48M |
| Shareholder's equity | -21.67M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -14383.79B |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -14383.79B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -7.74% |
| Return on Invested Capital | 15.28% |
| Cash Return on Invested Capital | 214748.36% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.51 |
| Daily high | 1.58 |
| Daily low | 1.50 |
| Daily Volume | 4K |
| All-time high | 117.60 |
| 1y analyst estimate | 5.00 |
| Beta | 0.17 |
| EPS (TTM) | -0.44 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 29 Apr 2025 |
Downside potential
Loading...
Downside potential data
| NERV | S&P500 | |
| Current price drop from All-time high | -98.67% | -12.04% |
| Highest price drop | -98.86% | -56.47% |
| Date of highest drop | 9 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -62.01% | -11.07% |
| Avg time to new high | 194 days | 12 days |
| Max time to new high | 1229 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
10.96M
Marketcap category
Small-cap
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Employees
9
Investor relations
-
SEC filings
CEO
Rémy Luthringer
Country
USA
City
Waltham
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page